[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT02940483 : Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma|
|Phase||Early Phase 1|
|Ages||Min: 1 Year Max: 21 Years|
- Diagnosis: Patients with histologically verified ependymoma, with recurrence or
progression involving anywhere in the brain and/or spine. To be eligible, patients'
disease must have originated in the posterior fossa of the brain.
- Patient must have either measurable or evaluable tumor as assessed by MRI of the brain
and total spine.
- An implanted catheter in the fourth ventricle or posterior fossa tumor cavity attached
to a ventricular access device or agreement to have one placed.
- A minimum of 7 days between last dose of systemic chemotherapy and/or radiation
therapy and first infusion of 5-Azacytidine into fourth ventricle.
- Life expectancy of at least 12 weeks in the opinion of the PI
- Lansky score of 50 or greater if =16 years of age or Karnofsky score of 50 or greater
if > 16 years of age.
- Existing neurological deficits must have been stable for a minimum of 1 week prior to
- Patients must have recovered from the acute toxic effects of all prior anticancer
- Adequate bone marrow function defined by peripheral absolute neutrophil count (ANC) =
500/µL, platelet count = 50,000/ µL (transfusion independent), and hemoglobin =9.0
gm/dL (may receive RBC transfusions)
- Patient or patient's legal representative, parent(s), or guardian able to provide
written informed consent.
- Enrolled in another treatment protocol
- Has received another investigational or chemotherapy agent or radiation therapy within
7 days prior to 5-Azacytidine infusion into the fourth ventricle.
- Evidence of untreated infection
- Pregnant of lactating women
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02940483
| Link to official Clinicaltrials.gov listing